List view / Grid view
16 July 2018 | By Catherine Lautenschlager (PerkinElmer), Hong Cao (PerkinElmer)
AlphaLISA® provides a robust assay that facilitates the design and development of antibody therapeutics.
11 July 2018 | By IDBS
This whitepaper explains how you can find ways to optimise the holistic preclinical development process...
3 July 2018 | By Adam David Thomas
In the annual report of the Chief Medical Officer, 1 Dame Sally Davies has declared that we are part of ‘generation genome’ – the era in which we reap the rewards of our advances in genomic technologies and improvements in our understanding of the whole genome in human health.
28 June 2018 | By Drug Target Review
Researchers have conducted promising preclinical experiments on a compound that could be used to treat Wilson's disease...
25 June 2018 | By Drug Target Review
Researchers show altering the molecular interactions between the flu virus and host genes stunts virus replication...
20 June 2018 | By Drug Target Review
Research scientists have solved a major problem in chemistry and drug development by using droplet-sized 'mini-ecosystems to quickly see if a molecule can function as a potential therapeutic...
18 June 2018 | By Drug Target Review
A metabolic hormone found in the venom and gut of Australia’s iconic platypus will now be investigated for its potential to treat type 2 diabetes...
15 June 2018 | By IntelliCyt
The Intellicyt Mouse IgG Type and Titer Kit is a high throughput, multiplexed assay kit that enables analyses of isotype, titer and cell health in a single assay...
15 June 2018 | By IntelliCyt Corporation
Analyse isotype titer and cell health in one assay...
11 June 2018 | By PerkinElmer
For lead optimisation, target-based assays are still the most affordable means of rapidly performing fast iterations and remain core to screening. However, the desire for biological relevance is driving ongoing growth in cell-based assays.
11 June 2018 | By Jeff McMillan (Senior Product Manager Imaging at Molecular Devices)
The global high-content screening (HCS) software and services market accounted for over $500 million in 2017 and is expected to reach approximately $1.4 billion by 2026, increasing at a compound annual growth rate of more than 11%, says Jeff McMillan, Senior Product Manager Imaging, Molecular Devices.
8 June 2018 | By Mark Paris
This webinar focused on a recent study evaluating a cohort of head and neck squamous cell carcinoma (HNSCC) patient tumours treated with anti-PD1 using CANscript™.
8 June 2018 | By Tecan
This webinar, supported by Tecan, focused on the automated assessment of liver and cardiac toxicities in lead optimisation, using biochemical and human iPS cell assays.
7 June 2018 | By Liz Quinn (Associate Director - Stem Cells Marketing at Takara Bio USA)
Human primary hepatocytes (hpheps) are the gold standard for in vitro evaluation of drug metabolism, drug-drug interactions, and metabolic disease research. However, hpheps don’t survive in standard 2D culture for very long – no longer than two or three days.
7 June 2018 | By Takara Bio
Human primary hepatocytes (hphep cells) are the gold standard for in vitro evaluation of drug metabolism, drug-drug interactions, safety assessment of drug candidates, and disease modeling.
Send this to a friend
Follow: